Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy

References

• Leonard WJ, Lin J-X, O’Shea JJ. The γc family of cytokines: basic biology to therapeutic ramifications. Immunity. 2019;50(4):832–12. doi:10.1016/j.immuni.2019.03.028.
   PubMed Web of Science ®Google Scholar
• Wang X, Lupardus P, LaPorte SL, Garcia KC. Structural biology of shared cytokine receptors. Annu Rev Immunol. 2009;27(1):29–60. doi:10.1146/annurev.immunol.24.021605.090616.
   PubMedGoogle Scholar
• Boulay J-L, O’Shea JJ, Paul WE. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity. 2003;19(2):159–63. doi:10.1016/S1074-7613(03)00211-5.
   PubMed Web of Science ®Google Scholar
• Feldmann M. Many cytokines are very useful therapeutic targets in disease. J Clin Invest. 2008;118(11):3533–36. doi:10.1172/JCI37346.
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Cytokines in Cancer Immunotherapy. Csh Perspect Biol. 2018;10(12):a028472. doi:10.1101/cshperspect.a028472.
   PubMed Web of Science ®Google Scholar
• Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I. Cytokines in clinical cancer immunotherapy. Brit J Cancer. 2019;120(1):6–15. doi:10.1038/s41416-018-0328-y.
   PubMed Web of Science ®Google Scholar
• Hutmacher C, Neri D. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy. Adv Drug Deliver Rev. 2018;141:67–91. doi:10.1016/j.addr.2018.09.002.
   PubMed Web of Science ®Google Scholar
• Ellerman D. Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods. 2019;154:102–17. doi:10.1016/j.ymeth.2018.10.026.
   PubMed Web of Science ®Google Scholar
• Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017;6(3):00–00. doi: 10.1080/2162402X.2016.1277306.
   Web of Science ®Google Scholar
• Dickopf S, Buldun C, Vasic V, Georges G, Hage C, Mayer K, Forster M, Wessels U, Stubenrauch K-G, Benz J, et al. Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies. Biol Chem. 2022;403(5–6):495–508. doi: 10.1515/hsz-2021-0401.
   PubMed Web of Science ®Google Scholar
• Dengl S, Mayer K, Bormann F, Duerr H, Hoffmann E, Nussbaum B, Tischler M, Wagner M, Kuglstatter A, Leibrock L, et al. Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices. Nat Commun. 2020;11(1):4974. doi: 10.1038/s41467-020-18477-7.
   PubMed Web of Science ®Google Scholar
• Venetz D, Koovely D, Weder B, Neri D. Targeted reconstitution of cytokine activity upon antigen binding using split cytokine antibody fusion proteins*. J Biol Chem. 2016;291(35):18139–47. doi:10.1074/jbc.M116.737734.
   PubMed Web of Science ®Google Scholar
• Quijano-Rubio A, Bhuiyan AM, Yang H, Leung I, Bello E, Ali LR, Zhangxu K, Perkins J, Chun J-H, Wang W, et al. A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy. Nat Biotechnol. 2022;41(4):532–40. doi: 10.1038/s41587-022-01510-z.
   PubMed Web of Science ®Google Scholar
• Nirschl CJ, Brodkin HR, Hicklin DJ, Ismail N, Morris K, Seidel-Dugan C, Steiner P, Steuert Z, Sullivan JM, Tyagi E, et al. Discovery of a conditionally activated interleukin-2 that promotes anti-tumor immunity and induces tumor regression. Cancer Immunol Res. 2022;10(5):581–96. doi: 10.1158/2326-6066.CIR-21-0831.
   PubMed Web of Science ®Google Scholar
• Hsu EJ, Cao X, Moon B, Bae J, Sun Z, Liu Z, Fu Y-X. A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy. Nat Commun. 2021;12(1):2768. doi:10.1038/s41467-021-22980-w.
   PubMed Web of Science ®Google Scholar
• Cao X, Liang Y, Hu Z, Li H, Yang J, Hsu EJ, Zhu J, Zhou J, Fu Y-X. Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance. Nat Commun. 2021;12(1):5866. doi:10.1038/s41467-021-26112-2.
   PubMed Web of Science ®Google Scholar
• Guo J, Liang Y, Xue D, Shen J, Cai Y, Zhu J, Fu Y-X, Peng H. Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. Cell Res. 2021;31(11):1190–98. doi:10.1038/s41422-021-00543-4.
   PubMed Web of Science ®Google Scholar
• Garcin G, Paul F, Staufenbiel M, Bordat Y, der HJ, Wilmes S, Cartron G, Apparailly F, Koker SD, Piehler J, et al. High efficiency cell-specific targeting of cytokine activity. Nat Commun. 2014;5(1):3016. doi: 10.1038/ncomms4016.
   PubMedGoogle Scholar
• Deak LC, Nicolini V, Hashimoto M, Karagianni M, Schwalie PC, Lauener L, Varypataki EM, Richard M, Bommer E, Sam J, et al. PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. Nature. 2022;610(7930):161–72. doi: 10.1038/s41586-022-05192-0.
   PubMed Web of Science ®Google Scholar
• Xu Y, Carrascosa LC, Yeung YA, Chu M-H, Yang W, Djuretic I, Pappas DC, Zeytounian J, Ge Z, de RV, et al. An engineered IL15 cytokine mutein fused to an Anti-PD-1 improves intratumoral T-Cell function and antitumor immunity. Cancer Immunol Res. 2021;9(10):1141–57. doi: 10.1158/2326-6066.CIR-21-0058.
   PubMed Web of Science ®Google Scholar
• Sarkar CA, Lowenhaupt K, Horan T, Boone TC, Tidor B, Lauffenburger DA. Rational cytokine design for increased lifetime and enhanced potency using pH-activated “histidine switching”. Nat Biotechnol. 2002;20(9):908–13. doi:10.1038/nbt725.
   PubMed Web of Science ®Google Scholar
• Gaggero S, Martinez-Fabregas J, Cozzani A, Fyfe PK, Leprohon M, Yang J, Thomasen FE, Winkelmann H, Magnez R, Conti AG, et al. IL-2 is inactivated by the acidic pH environment of tumors enabling engineering of a pH-selective mutein. Sci Immunol. 2022;7(78):eade5686. doi: 10.1126/sciimmunol.ade5686.
   PubMed Web of Science ®Google Scholar
• Heeb LEM, Egholm C, Boyman O. Evolution and function of interleukin-4 receptor signaling in adaptive immunity and neutrophils. Genes Immun. 2020;21(3):143–49. doi:10.1038/s41435-020-0095-7.
   PubMed Web of Science ®Google Scholar
• Junttila IS. Tuning the cytokine responses: An update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. 2018;9:888. doi:10.3389/fimmu.2018.00888.
   PubMed Web of Science ®Google Scholar
• Paul WE. History of interleukin-4. Cytokine. 2015;75(1):3–7. doi:10.1016/j.cyto.2015.01.038.
   PubMed Web of Science ®Google Scholar
• Wlodaver A, Pavlovsky A, Gustchina A. Crystal structure of human recombinant interleukin‐4 at 2.25 Å resolution. FEBS Lett. 1992;309(1):59–64. doi:10.1016/0014-5793(92)80739-4.
   PubMed Web of Science ®Google Scholar
• Walter MR, Cook WJ, Zhao BG, Cameron RP, Ealick SE, Walter RL, Reichert P, Nagabhushan TL, Trotta PP, Bugg CE. Crystal structure of recombinant human interleukin-4. J Biol Chem. 1992;267(28):20371–76. doi:10.1016/S0021-9258(19)88711-2.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Puri RK, Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci. 1994;91(15):6889–93. doi:10.1073/pnas.91.15.6889.
   PubMed Web of Science ®Google Scholar
• Dolberg TB, Meger AT, Boucher JD, Corcoran WK, Schauer EE, Prybutok AN, Raman S, Leonard JN. Computation-guided optimization of split protein systems. Nat Chem Biol. 2021;17(5):531–39. doi:10.1038/s41589-020-00729-8.
   PubMed Web of Science ®Google Scholar
• Mayer K, Baumann A-L, Grote M, Seeber S, Kettenberger H, Breuer S, Killian T, Schäfer W, Brinkmann U. TriFabs—Trivalent IgG-Shaped bispecific antibody derivatives: design, generation, characterization and application for targeted payload delivery. Int J Mol Sci. 2015;16(11):27497–507. doi:10.3390/ijms161126037.
   PubMed Web of Science ®Google Scholar
• Dickopf S, Lauer ME, Ringler P, Spick C, Kern P, Brinkmann U. Highly flexible, IgG-shaped, trivalent antibodies effectively target tumor cells and induce T cell-mediated killing. Biol Chem. 2019;400(3):343–50. doi:10.1515/hsz-2018-0338.
   PubMed Web of Science ®Google Scholar
• Wang Y, Shen B-J, Sebald W. A mixed-charge pair in human interleukin 4 dominates high-affinity interaction with the receptor α chain. Proc Natl Acad Sci. 1997;94:1657–62. doi:10.1073/pnas.94.5.1657.
   PubMed Web of Science ®Google Scholar
• Kruse N, Shen BJ, Arnold S, Tony HP, Müller T, Sebald W. Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation. Embo J. 1993;12(13):5121–29. doi:10.1002/j.1460-2075.1993.tb06207.x.
   PubMed Web of Science ®Google Scholar
• LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, Heller NM, Keegan AD, Garcia KC. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell. 2008;132(2):259–72. doi:10.1016/j.cell.2007.12.030.
   PubMed Web of Science ®Google Scholar
• Hage T, Sebald W, Reinemer P. Crystal structure of the interleukin-4/Receptor α chain complex reveals a mosaic binding interface. Cell. 1999;97(2):271–81. doi:10.1016/S0092-8674(00)80736-9.
   PubMed Web of Science ®Google Scholar
• Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, Piao Y, Miyazono K, Urabe A, Takaku F. Establishment and characterization of a unique human cell line that proliferates dependently on GM‐CSF, IL‐3, or erythropoietin. J Cell Physiol. 1989;140(2):323–34. doi:10.1002/jcp.1041400219.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS, Heffner TL, Gupta VA, Sullivan HC, Neish AS, Dhodapkar MV, Lonial S. Daratumumab in multiple myeloma. Cancer. 2019;125(14):2364–82. doi:10.1002/cncr.32065.
   PubMed Web of Science ®Google Scholar
• Hogan KA, Chini CCS, Chini EN. The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases. Front Immunol. 2019;10:1187. doi:10.3389/fimmu.2019.01187.
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Gonzalez-Nicolini V, Freimoser-Grundschober A, Nayak TK, Fahrni L, Hosse RJ, Gerrits D, Geven EJW, Sam J, Lang S, et al. Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. MAbs. 2021;13(1):1913791. doi: 10.1080/19420862.2021.1913791.
   PubMed Web of Science ®Google Scholar
• Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011. doi:10.1038/mto.2016.11.
   PubMed Web of Science ®Google Scholar
• Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody–drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327–44. doi:10.1038/s41571-021-00470-8.
   PubMed Web of Science ®Google Scholar
• Geiger M, Stubenrauch K-G, Sam J, Richter WF, Jordan G, Eckmann J, Hage C, Nicolini V, Freimoser-Grundschober A, Ritter M, et al. Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. Nat Commun. 2020;11(1):3196. doi: 10.1038/s41467-020-16838-w.
   PubMed Web of Science ®Google Scholar
• Boustany LM, LaPorte SL, Wong L, White C, Vinod V, Shen J, Yu W, Koditek D, Winter MB, Moore S, et al. A probody T cell–engaging bispecific antibody targeting EGFR and CD3 inhibits colon cancer growth with limited toxicity. Cancer Res. 2022;82(22):4288–98. doi: 10.1158/0008-5472.CAN-21-2483.
   PubMed Web of Science ®Google Scholar
• Panchal A, Seto P, Wall R, Hillier BJ, Zhu Y, Krakow J, Datt A, Pongo E, Bagheri A, Chen T-H, et al. COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors. MAbs. 2020;12(1):1792130. doi: 10.1080/19420862.2020.1792130.
   PubMed Web of Science ®Google Scholar
• Banaszek A, Bumm TGP, Nowotny B, Geis M, Jacob K, Wölfl M, Trebing J, Kucka K, Kouhestani D, Gogishvili T, et al. On-target restoration of a split T cell-engaging antibody for precision immunotherapy. Nat Commun. 2019;10(1):5387. doi: 10.1038/s41467-019-13196-0.
   PubMedGoogle Scholar
• Kermer V, Baum V, Hornig N, Kontermann RE, Müller D. An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site. Mol Cancer Ther. 2012;11(6):1279–88. doi:10.1158/1535-7163.MCT-12-0019.
   PubMed Web of Science ®Google Scholar
• Nitto CD, Neri D, Weiss T, Weller M, Luca RD. Design and characterization of novel antibody-cytokine fusion proteins based on interleukin-21. Antibodies. 2022;11(1):19. doi:10.3390/antib11010019.
   Web of Science ®Google Scholar
• Hess C, Neri D. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6. Protein Eng Des Sel. 2014;27(6):207–13. doi:10.1093/protein/gzu013.
   PubMed Web of Science ®Google Scholar
• Nemergut M, Žoldák G, Schaefer JV, Kast F, Miškovský P, Plückthun A, Sedlák E. Analysis of IgG kinetic stability by differential scanning calorimetry, probe fluorescence and light scattering. Protein Sci. 2017;26(11):2229–39. doi:10.1002/pro.3278.
   PubMed Web of Science ®Google Scholar
• Dickopf S, Georges GJ, Brinkmann U. Format and geometries matter: structure-based design defines the functionality of bispecific antibodies. Comput Struct Biotechnol J. 2020;18:1221–27. doi:10.1016/j.csbj.2020.05.006.
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai Y-T, van der Veer MS, Bakker JM, Vink T, Jacobs DCH, Oomen LA, Peipp M, Valerius T, Slootstra JW, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. The Journal Of Immunology. 2011;186(3):1840–48. doi: 10.4049/jimmunol.1003032.
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci. 1992;89(10):4285–89. doi:10.1073/pnas.89.10.4285.
   PubMed Web of Science ®Google Scholar
• Metz S, Haas AK, Daub K, Croasdale R, Stracke J, Lau W, Georges G, Josel H-P, Dziadek S, Hopfner K-P, et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci. 2011;108(20):8194–99. doi: 10.1073/pnas.1018565108.
   PubMed Web of Science ®Google Scholar
• Ridgway JBB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng Des Sel. 1996;9(7):617–21. doi:10.1093/protein/9.7.617.
   Google Scholar
• Czekanska EM. Mammalian Cell Viability. In: Stoddart, M editor. Assessment of Cell Proliferation with Resazurin-Based Fluorescent Dye. Humana Press; 2011;740:27–32. doi:10.1007/978-1-61779-108-6_5.
   Google Scholar